+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Glaucoma treatment Market Research and Forecast 2018-2023

  • ID: 4621256
  • Report
  • August 2018
  • Region: Global
  • Orion Market Research Private Limited
until Dec 31st 2021


  • Akorn, Inc.
  • Bayer Ag
  • Hoya Corporation
  • Johnson & Johnson
  • Novartis International Ag
  • Sanofi S.A.
The Glaucoma is one of the major eyes disorders which causes damage to the optic nerve. Glaucoma can result in vision loss and blindness. There are various drugs used for the diagnosis of this disease. Some of them are Beta blocker, Alpha-adrenergic agonists, Hyperosmotics, and Carbonic anhydrase inhibitors. The global glaucoma treatment market is emerging with a rapid speed due to some of the major factors such as growing incidences of glaucoma diseases across the globe. Increasing old age population in various regions has become one of the reasons for the growth of this market. Various initiatives by the government and healthcare institutions in order to cure glaucoma related problems have helped for the growth of this segment. The market is also driven by favourable reimbursement policies related to glaucoma treatment.

The continuous innovations in the drugs and rising number of patients with diabetes have resulted in significant growth opportunities. Although there are some factors which hinders the growth of market. This comprise of lack of awareness about the disease and its treatment in various developing and underdeveloped regions, and postoperative complications resulting after glaucoma surgery.

Global glaucoma treatment market is studied on the basis of three segments: products, disease indication, end user and drug class. Based on the product, the market is further subdivided as glaucoma drainage devices, implants and stents and glaucoma laser devices. On the basis of disease indication, the market is sub-segmented as closed angle glaucoma, open angle glaucoma, congenital glaucoma and secondary glaucoma. The open angle glaucoma (OAG) and closed angle glaucoma (CAG) are the most common types of glaucoma. According to the International Council of Ophthalmology report, open angle and closed angle glaucoma individually account for about half of all glaucoma cases. In addition, they are responsible for the major cause of irreversible vision across the globe. Therefore, Open angle glaucoma and angle closure glaucoma segments are expected to have the highest share of glaucoma treatment market. Furthermore, according to the end user, the market is bifurcated as hospitals, eye care clinics and home care. According to the drug class, the market is diversified as prostaglandin analogues, alpha agonist, cholinergic, beta blockers and carbonic anhydrase inhibitors.

Considering geographic regions, North American dominate the market due to high prevalence of glaucoma, and economic stability which results to high healthcare expenditure. Europe has good scope of the market due to its capability of strong reimbursement policies and high presence of patient’s pool. Asia Pacific region considered as the fastest growing market with the rising number of patients and emerging healthcare spending.

The companies contributing in the global market consists of Aeries Pharmaceuticals, Akron, Allergan, Bausch & Lomb Incorporation, Inotek Pharmaceuticals, Novartis, Aura Lab, Valeant pharmaceuticals, Johnson & Johnson, Hoya Corporation, and Sunways.

Research Methodology:

The market study of glaucoma treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as Glaucoma Research Foundation, National Eye Institute, Lions Eye Institute, World Glaucoma Association others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalogue
  • Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for glaucoma drug manufacturers and suppliers, healthcare provider, research and development companies, contract manufacturing organizations, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms. The report will be delivering insights into the market for better business decisions.

Market Segmentation:

Global Glaucoma treatment market is segmented on the basis of regional outlook and following segments:
1. Global Glaucoma treatment Market Research and Analysis, By Products
2. Global Glaucoma treatment Market Research and Analysis, By Disease Indication
3. Global Glaucoma treatment Market Research and Analysis, By End User
4. Global Glaucoma treatment Market Research and Analysis, By Drug class
5. Global Glaucoma treatment Market Research and Analysis, By Region

The Report Covers
  • Comprehensive research methodology of global glaucoma treatment
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global glaucoma treatment market.
  • Insights about market determinants which are stimulating the global glaucoma treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown


  • Akorn, Inc.
  • Bayer Ag
  • Hoya Corporation
  • Johnson & Johnson
  • Novartis International Ag
  • Sanofi S.A.
1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview And Insights
2.1. Definition
2.2. Analyst Insights &Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulations
2.3.1. United States
2.3.2. European Union
2.3.3. China
2.3.4. India
2.3.5. Rest Of The World
2.4. Pipeline Analysis

3. Market Determinant
3.1. Motivators
3.1.1. High Incidences Of Glaucoma Diseases Coupled With Geriatric Population
3.1.2. Rising Demand For Minimally Invasive Surgery For Glaucoma Treatment
3.1.3. Innovations In Products And Technologies Such As Xen Gel Stent
3.1.4. Initiatives By Government And Healthcare Institutions
3.2. Restraints
3.2.1. Lack Of Awareness In Developing And Underdeveloped Economies
3.2.2. Postoperative Complications After Glaucoma Surgery
3.3. Opportunities
3.3.1. Rising Investments By Key Players
3.3.2. Glaucoma Drugs In Pipeline

4. Market Segmentation
4.1. By Products
4.1.1. Glaucoma Drainage Devices
4.1.2. Implants And Stents
4.1.3. Glaucoma Laser Devices
4.2. By Disease Indication
4.2.1. Closed Angle Glaucoma (Cag)
4.2.2. Open Angle Glaucoma (Oag)
4.2.3. Secondary Glaucoma
4.2.4. Congenital Glaucoma
4.3. By End User
4.3.1. Hospitals
4.3.2. Eye Care Clinics
4.3.3. Home Care
4.4. By Drug Class
4.4.1. Prostaglandin Analogues
4.4.2. Alpha Agonist
4.4.3. Cholinergic
4.4.4. Beta Blockers
4.4.5. Carbonic Anhydrase Inhibitors

5. Competitive Landscape
5.1. Key Market Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.1.3. Rest Of North America
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest Of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.4. Rest Of The World

7. Company Profiles
7.1. Aerie Pharmaceuticals Inc.
7.2. Akorn, Inc.
7.3. Allergan Plc
7.4. Bausch & Lomb Incorporation
7.5. Bayer Ag
7.6. Carl Zeiss Ag
7.7. F. Hoffmann-La Roche, Ltd.
7.8. Hoya Corporation
7.9. Inotek Pharmaceuticals Corporation
7.10. Ivantis, Inc.
7.11. Johnson & Johnson
7.12. Merck & Co., Inc.
7.13. Novartis International Ag
7.14. Pfizer, Inc.
7.15. Regeneron Pharmaceuticals, Inc.
7.16. Sanofi S.A.
7.17. Santen Pharmaceuticals Co., Ltd.
7.18. Teva Pharmaceuticals Industries, Ltd.
7.19. Topcon Corporation
7.20. Valeant Pharmaceuticals International, Inc.
7.21. Sunways
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aerie Pharmaceuticals Inc.
  • Akorn, Inc.
  • Allergan Plc
  • Bausch & Lomb Incorporation
  • Bayer Ag
  • Carl Zeiss Ag
  • F. Hoffmann-La Roche, Ltd.
  • Hoya Corporation
  • Inotek Pharmaceuticals Corporation
  • Ivantis, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International Ag
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Santen Pharmaceuticals Co., Ltd.
  • Teva Pharmaceuticals Industries, Ltd.
  • Topcon Corporation
  • Valeant Pharmaceuticals International, Inc.
  • Sunways
Note: Product cover images may vary from those shown